Literature DB >> 1665402

Itraconazole penetrates the nail via the nail matrix and the nail bed--an investigation in onychomycosis.

L Matthieu1, P De Doncker, G Cauwenbergh, R Woestenborghs, V van de Velde, P A Janssen, P Dockx.   

Abstract

Nail-matrix kinetics were studied in 21 patients (19 with onychomycosis, two with tinea corporis) as soon as taking itraconazole (Sporanox) 100 mg daily for up to 7 months. Itraconazole was detected in the distal nail as soon as 1 month after the start of therapy (42 ng/g in fingernails and 16 ng/g in toenails). During the course of treatment, this concentration rose and reached a mean of 160 ng/g in fingernail clippings and 197 ng/g in toenail clippings. Moreover, in fingernails of 12 out of 21 patients and in toenails of six out of 20 patients, itraconazole was detected in the distal nail clippings before full outgrowth of the fastest-growing nail. In most patients, itraconazole was detected in the distal nail clippings earlier than would be expected if the drug were incorporated only via the nail matrix, indicating that in addition to the nail matrix, a second route of penetration into the nail exists, i.e. the nail bed.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1665402     DOI: 10.1111/j.1365-2230.1991.tb00405.x

Source DB:  PubMed          Journal:  Clin Exp Dermatol        ISSN: 0307-6938            Impact factor:   3.470


  11 in total

Review 1.  Drugs in nails: physiology, pharmacokinetics and forensic toxicology.

Authors:  A Palmeri; S Pichini; R Pacifici; P Zuccaro; A Lopez
Journal:  Clin Pharmacokinet       Date:  2000-02       Impact factor: 6.447

Review 2.  Onychomycosis. Going for cure.

Authors:  A K Gupta; N H Shear
Journal:  Can Fam Physician       Date:  1997-02       Impact factor: 3.275

Review 3.  Clinical and economic factors in the treatment of onychomycosis.

Authors:  T R Einarson; A K Gupta; N H Shear; S Arikian
Journal:  Pharmacoeconomics       Date:  1996-04       Impact factor: 4.981

Review 4.  Pharmacokinetics of antifungal agents in onychomycoses.

Authors:  D Debruyne; A Coquerel
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

5.  Determination of posaconazole levels in toenails of adults with onychomycosis following oral treatment with four regimens of posaconazole for 12 or 24 weeks.

Authors:  Gopal Krishna; Lei Ma; Monika Martinho; Pratapa Prasad; Janice Wahl; Amir Tavakkol
Journal:  Antimicrob Agents Chemother       Date:  2011-07-11       Impact factor: 5.191

Review 6.  Pharmacology of itraconazole.

Authors:  K De Beule; J Van Gestel
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 7.  Itraconazole. A reappraisal of its pharmacological properties and therapeutic use in the management of superficial fungal infections.

Authors:  M Haria; H M Bryson; K L Goa
Journal:  Drugs       Date:  1996-04       Impact factor: 9.546

Review 8.  Treatment and prophylaxis of tinea infections.

Authors:  G E Piérard; J E Arrese; C Piérard-Franchimont
Journal:  Drugs       Date:  1996-08       Impact factor: 9.546

Review 9.  Pharmacokinetic optimisation of oral antifungal therapy.

Authors:  M Schäfer-Korting
Journal:  Clin Pharmacokinet       Date:  1993-10       Impact factor: 6.447

Review 10.  Onychomycosis: pathogenesis, diagnosis, and management.

Authors:  B E Elewski
Journal:  Clin Microbiol Rev       Date:  1998-07       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.